Hypertension and diabetes are widespread diseases in our modern society and due to the comfortable, but often unhealthy "western world" lifestyle, the population suffering from its consequences is constantly growing. Vascular pathologies affect the body's entire vascular system subsequently including the circulation and vessels in the eye. For these reasons, after diabetic retinopathy and vein occlusions rank among the most common vascular disorders of the retina, with the highest incidence in a population over the age of 60. As to prevent severe vision loss due to complications induced by these angiopathies, panretinal or segmental laser coagulation is recommended as standard treatment of proliferative retinopathy. So far patients who undergo panretinal coagulation typically receive between 1200 and 1500 lasers spots in two to four sessions over the course of 2 to 4 weeks. Clinical guidelines recommend not exceeding the number of more than 900 applied laser spots per session, due to the development of possible reversible exudative reaction e.g. macular edema. However, the performance of a panretinal photocoagulation is so far a time consuming procedure which is generally painful for the patient. For these reasons new laser systems were developed aiming to solve these obvious drawbacks. Main improvement of these systems is the reduction of the laser burn durations per spot and to enable therefore the rapid application of a large number of spots in a preset pattern. Treatment with reduced pulse duration is associated with less pain for the patient and, compared to several sessions requiring about 30 minutes each when using a conventional laser system, treatment time for a complete panretinal treatment could be significantly reduced. The PASCAL® Laser (Pattern Scan Laser, OptiMedica® Corporation, Santa Clara, CA, USA) is a new commercially available laser system confirming all these requirements.